EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSEEEG00000021684
Gene Symbol: FGFR3
2 Cross references
194 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSEEEG00000013838
Gene Symbol: FLT1
4 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSEEEG00000008806
Gene Symbol: FLT4
4 Cross references
197 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSEEEG00000004204
Gene Symbol: FOLR
4 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSEEEG00000016483
Gene Symbol: FSHR
4 Cross references
201 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSEEEG00000007333
Gene Symbol: LOC113578365
4 Cross references
319 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSEEEG00000005550
Gene Symbol: FRK
2 Cross references
217 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSEEEG00000018619
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSEEEG00000004742
Gene Symbol: GABRA1
1 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSEEEG00000020545
Gene Symbol: GABRA3
4 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSEEEG00000016030
Gene Symbol: GABRA4
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSEEEG00000018521
Gene Symbol: GABRA5
4 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).